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ABSTRACT
A platinum(II) complex with the antiviral drug acyclovir was synthesized and its
antiviral and anticancer properties were investigated in comparison to those of acyclovir and
cisplatin. The platinum-acyclovir complex maintained the antiviral activity of the parent
drug acyclovir, though showing a minor efficacy on a molar basis (IDs0 7.85 and 1.02 laM
for platinum-acyclovir and cisplatin, respectively). As anticancer agent, the platinum-
acyclovir complex was markedly less potent than cisplatin on a mole-equivalent basis, but it
was as effective as cisplatin when equitoxic dosages were administered in vivo to P388
leukaemia-bearing mice (%T/C 209 and 211 for platinum-acyclovir and cisplatin,
respectively). The platinum-acyclovir complex was also active against a cisplatin-resistant
subline of the P388 leukaemia (%T/C 140), thus suggesting a different mechanism of
action. The DNA interaction properties (sequence specificity and interstrand cross-linking
ability) of platinum-acyclovir were also investigated in comparison to those of cisplatin and
[Pt(dien)C1]+, an antitumour-inactive platinum-triamine compound. The results of this study
point to a potential new drug endowed, at the same time, with antiviral and anticancer
activity and characterized by DNA interaction properties different from those of cisplatin.
INTRODUCTION
Acyclovir (9-(2-hydroxyethoxymethyl)guanine, acycloguanosine) and cisplatin (cis-
diaminedichloroplatinum(II), cis-DDP) are two drugs currently used in antiviral and
anticancer therapy, respectively.
Acyclovir is a nucleoside analogue with potent activity towards herpes virus
infections. Acyclovirtriphosphate is preferentially formed in infected cells and inhibits viral
DNA synthesis either selectively interfering with viral DNA polymerase or leading to
premature chain termination (1).
The metal-coordinating properties of acyclovir are of current interest (2-5) from a
mechanistic point of view, some DNA polymerases containing (Zn2+) and/or being
2+ Mn2+ r 2+ activated by metal ions (Mg o Co ). Moreover, metal complexes of acyclovir
may exhibit antiviral activity different from that ofthe free ligand (6).
Cisplatin is one ofthe most successful antitumour drugs developed in recent years and
numerous studies have revealed that its cytotoxic activity depends upon the interaction with
cellular DNA. Cisplatin and related platinum(II) analogues coordinate two neighbouring
purines, thus producing bifunctional lesions able to inhibit DNA replication and/or
transcription (7). Platinum(II) complexes with nucleosides and nucleoside analogues are
also of current interest as model compounds; moreover, platinum(II) complexes with
nucleotide derivatives of formula [PtCI(NH3)2(Am)]+ (Am pyrimidine or purine
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derivative) have recently demonstrated activity in prclinical tumour screens, thus
suggesting that also monofunctional DNA lesions might determine a cytotoxic effect (8).
In our search on the platinum-coordination properties of acyclovir we synthesized a
compound derived from cisplatin. The antiviral and antitumour properties of such a
compound, cis-[PtCl(NH3)2(acyclovir)]N03, have been investigated and compared to
those of acyclovir and cisplatin. Moreover, preliminary studies on the DNA interaction
properties of this platinum-acyclovir complex are reported. The restflts point to a potential
new drug endowed, at the same time, with antiviral and antitumour properties.
MATERIALS AND METHODS
Synthesis of the complexes. 9-(2-hydroxyethoxymethyl)guanine (acyclovir, L 1), 9-(2-
acethoxyethoxymethyl)guanine (monoacetylacyclovir, L2) and 9-(2-acetoxyethoxymethyl)-
N(2)-acetylguanine (diacetylacyclovir, L3) were prepared by the method of Matsumoto et
al. (9).
Preparation of cis-[PtCI2(NH3)(L1)] (1) The compound was prepared by the
method of Pochon and Kong (10) by bridge splitting with acyclovir of the dimer
[PtI2(NH3)]2 obtained from reaction of cis-[PtI2OqI-I3)2] with perchloric acid. The chloro
compound could be obtained from the corresponding iodo species by precipitating the iodo
ligands with a silver salt and adding KCI. The desidered product was formed in less than
50% yield and was accompanied by two major byproducts; the low solubility prevented
their separation and full characterization. Anal. Calcd for C8H14N603PtCI2: C, 12.8; H,
1.9; N, 11.3. Found: C, 13.2; H, 2.0; N, 11.4%.
Preparation of cis-[PtCl2L2] (L L2, 2; L3, 3). The complexes were prepared by
reaction of K2[PtC14] and L in 1:2 molar ratio. Thus K2[PtCI4] (0.20 g, 0.5 mmol) in
water (50 ml) was treated with L (1 mmol) and the suspension was left to stir at room
temperature for 3 d. The yellow precipitate was collected, washed with water, then with
methanol, and finally with ether. Yield 80%. Found: C, 30.6; H, 3.3; CI, 9.9; N, 17.6. Calc.
for C20H26CI2N1008Pt 2" C, 30.0; H, 3.3; CI, 8.9; N, 17.5. Found: C, 32.3; H, 3.3; CI,
8.3; N, 16.0. Calc. for C24H30CI2N100,10Pt 3: C, 32.6; H, 3.4; CI, 8.0; N, 15.8%.
Preparation of cis-[PtCI(NH3)2(L)]NO3 (4). This complex was prepared from cis-
[PtCI2(NH3)2] and L1 according to the method of Hollis et al. (11). Cis-[PtCI2(NH3)2]
(0.30 g, 1 mmol) and AgNO3 (0.15 g, 0.9 mmol) were stirred in dimethylformamide
(DMFA) (30 ml) for 1 d. The resulting mixture was filtered and the stoichiometric amount
ofL1 (0.22 g, 1 mmol) was added to the filtrate. Stirring was resumed and continued for 1
d. After a second filtration, the solution was taken to dryness and the residue crystallized
from water. Yield 70%. Found: C, 17.4; H, 3.1; CI, 6.7; N, 20.2; Calc. for
C8H17C1N806Pt 4: C, 17.4; H, 3.1; CI, 6.4; N, 20.3%.
Physical Measurements. Infrared spectra in the range 4000-400 cm-1 were recorded
as KBr pellets; spectra in the range 400-200 cm-1 were recorded as Polythene pellets on
Perkin-Elmer 283 and FT 1600 spectrophotometers. Proton NMR spectra were obtained
with Varian XL200 and Bruker AM 300 spectrometers.
Antiviral activity. The antiviral activity was evaluated in vitro by the plaque reduction
assay. For this purpose, 24 h growth VERO cell monolayers in 60 mm Petri dishes were
infected with 0.5 ml of a Herpes Simplex-1 virus stock solution containing 500 Plaque
Forming Units/ml. After 1 h incubation at 37 C the dishes were washed twice with sterile
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PBS and a semisolid maintenance medium containing the drug under study was added. Each
drug concentration was tested in triplicate and in three control cultures the cell medium
contained only the appropriate amount of drug solvent (DMSO). After 48 h incubation, cell
monolayers were fixed with methanol for 20 min, stained with Giemsa stain for 15 min and
then the cytolysis plaques were counted. The 50% inhibitory concentrations (ID50) were
derived by interpolation from a log-linear plot of concentration-per cent plaque reduction
outcomes.
Antitumour activity. The P388 murine leukaemia was used to evaluate the in vitro and
in vivo anticancer activity of the platinum complexes. The in vitro growth inhibitory effect
was evaluated by treating P388 cells in exponential growth phase (105cells/ml in RPMI
1640 medium supplemented with 10% foetal bovine serum and 10 lag/ml Kanamycin) with
increasing concentrations of platinum complexes freshly dissolved in serum-free medium.
After 1 h incubation at 37 C, the cells were washed twice with PBS and incubated in drug-
free medium for an additional 48 h; the number of viable cells was measured (trypan blue
exclusion test) and growth inhibition calculated as percentage of control. ID50 values were
derived from a log-linear plot of concentration-inhibition outcomes.
The in vivo antileukaemic effect of platinum complexes was evaluated on the P388
leukaemia, obtained as frozen stock from the National Cancer Institute (U.S.A.), and on a
cisplatin-resistant subline of P388 (P388/DDP) which was established in vivo in our
laboratory by!.p, treatment with a single dose of cisplatin (6 mg/kg) given 2 days after the
passage of 10 leukaemic cells over successive generations in B6D2F 1 mice (Charles River,
Italy). P388 and P388/DDP cells (106/mouse) were implanted i.p. into B6D2F1 mice (6
animals/group, 8 controls). Platinum complexes were dissolved in water just before use and
administered i.p. (0.1 ml per 10 g body weight) on days 1-7 at equitoxic dosages,
corresponding to LD0.05 (12). Antitumour activity was expressed as %(T/C), with T the
mean survival time oftreated mice and C that ofuntreated controls.
Primer extension footprinting assay. The sequence selectivity ofDNA modification
by platinum complexes was evaluated by the primer extension footprinting assay (13, 14).
PBR 322 double stranded DNA (1.5x10-8 mol nucleotides) was reacted with platinum
complexes (drug/nucleotide molar ratio 0.02) in a total volume of 10 lal of 10 mM Tris-
HC1, 1 mM EDTA, pH 8, for 1 h at 37 C. At the end of reaction time excess drug was
removed by centrifugation through Sephadex G-50 columns. After alkaline denaturation the
DNA was primed with 16-mer pst(+) primer (New England Biolabs) and the synthesis
erformed by Sequenase 2 enzyme (United States Biochemicals) in the presence of [a-
2p]dATP (370 KBq, 111 TBq/mmol) (Amersham) and unlabeled dNTPs following the
manufacturer protocol. The products of synthesis were electrophoresed (6%
polyacrylamide/7M urea gel) in parallel to a sequence ladder performed on unreacted DNA.
The autoradiography was performed overnight with Kodak Ektamat G film.
DNA interstrand cross-links. The kinetics of interstrand cross-link formation of
platinum complexes was evaluated in vitro by gel electrophoresis under denaturing
conditions, as described by Lemaire et al (15). The 3000-bp pGEM-7Zf(+) DNA
(Promega) linearized by Eco RI endonuclease (New England Biolabs) was mixed with
platinum complexes at (D/N)f 0.001 and then incubated in 10 mM NaCIO4 at 37 C. At
different time intervals, the cross-linking reaction was stopped by adjusting the NaOH
concentration to 10 mM and cooling the samples at 20 C. The samples were then
analyzed on a denaturing 1% agarose gel where DNA fragments containing interstrand
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cross-links migrated slower than fragments without interstrand cross-links. The percentage
of interstrand cross-linking was calculated from a densitometric scan of resulting bands.
RESULTS AND DISCUSSION
The structure of acyclovir (L1) is strikingly similar to that of guanosine but the rigid
dbofuranosyl ring has been substituted by the more flexible 2-hydroxyethoxymthyl acyclic
chain C(I’)H2OC(2’)H2C(3’)H2OH. Moreover two derivatives acetylated at the 2-
hydroxyethoxy position (L2) and at both 2-hydroxyethoxy and 2-amino positions (L3) have
also been used. The acetyl groups confer different solubility characteristics to the ligands
and related complexes, but should not modify N(7) coordination. The synthesis and crystal
structure of [Pt(2-C2H4)CI2(L1)] have been reported previously (16).
Compounds of three different t},pes: cis-[PtCl2(NH3)(L1)], 1, cis-[PtCl2(L)2] (L
L2, 2; L3, 3) and cis-[PtCI(NH3)2(L)]NO3 4, were synthesized and characterized. The
choise of these classes of compounds was based on reports of antitumour activity of
compounds having similar structures (8, 17, 18).
Rochon and Kong have provided a very convenient method for the preparation of
mixed amine complexes of formula cis-[PtI2(L)(L’)]. It is suggested, when synthesizing
compounds of the type cis-[PtI2(NH3)(L’)], to start with the amine L since the NH3 dimer
is more difficult to obtain and the yield is poorer. However, in the case of acyclovir (L1) the
obtainment of the dimeric, iodo-bridged, species is considerably more difficult than with
ammine. Compound 1 showed extremely low solubility even in solvents such as DMSO and
DMF thus preventing the possibility ofbiological studies.
The synthesis of cis-[PtCl2(L)2] complexes is straightforward starting from
K2[PtC14] and free ligand in molar ratio 1:2. The yield was quantitative and gave a single
pure product only in the case ofL2 (2) and L3 (3).
Cis-[PtCI(NHa)2(LI)]NOa (4) was prepared in good yield by the method of Hollis et
al. (11).
For complexes 2-4 theNMR spectra revealed a downfield shift ofthe H(8) signal and,
in non protic solvents, the presence of a signal attributable to N(1)H. These results indicate
that in all complexes N(7) coordination occurs. Compound 1 had a very poor solubility also
in solvents such as DMSO and DMF so that it could not be characterized by NMR
spectroscopy. However it is assumed that the acyclovir ligand keeps the N(7) coordination
found in the dimer precursor [Pt(L1)]2 from which it was obtained by bridge splitting with
ammonia. Moreover IR spectra indicate the presence of chlorine ligands in cis position.
Only compound 4 had solubility in water suitable for biological investigation and
therefore its antiviral and anticancer properties were investigated in comparison to those of
the parent drugs.
The anti-herpes simplex-1 activity of equimolar concentrations of platinum-acyclovir
and acyclovir complexes is reported in table I as mean number of cytolysis plaques and %
plaque reduction on VERO cells.
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Table I. Anti Herpes Simplex-1 Virus activity of acyclovir and platinum-acyclovir complex
(4).
Complex Concentration (laM) Plaque Number % Plaque reduction
Vehicle 256.3
Acyclovir 10 4.0 98.4
1.0 140.7 45.1
Pt-acyclovir (4) 10 119.7 53.3
1.0 200.3 21.8
0.1 263.0 0
The platinum-acyclovir complex mantains the antiviral activity of the parent drug
acyclovir, though showing a minor efficacy on a molar basis (ID50 7.85 and 1.02 laM for
platinum-acyclovir and acyclovir, respectively). This behaviour might be attributable to a
minor affinity of the viral thymidine kinase and/or of the host cell kinases for the platinum-
acyclovir complex as compared to acyclovir.
The effects of platinum-acyclovir complex in the murine P388 leukaemia system are
reported in table II.
Table II. In vitro and in vivo antileukaemic activity (P388 system) ofatinum complexes.
in vitro a in vivo
.Complex ID50 (taM) Dose (mg/kg) P388 P388/DDP
Pt-acyclovir (4) 108 50 209 140
cisplatin 2 0.6 211 97
a ID50 complex concentration inhibiting 50% cell growth.
b The effects on survival time of tumour-bearing mice are expressed as %TIC, i.e. mean
survival time (x100) oftreated animals versus controls.
The platinum-acyclovir complex shows an in vitro growth inhibitory capability,
expressed as 50% growth inhibitory concentration (ID50) markedly lower than that of
cisplatin: ID50 108 and 2 laM, respectively. Nevertheless, the platinum-acyclovir complex
has a selective in vivo antitumour activity and shows the same efficacy of cisplatin in
increasing the life span of animals treated with equitoxic dosages of the two componds
(%T/C 209 and 211, respectively). Moreover, compound 4 is active against a cisplatin-
resistant subline of the P388 leukaemia (%T/C 140). Similarly to cationic platinum
triamine complexes synthesized by Hollis (8, 11), the platinum-acyclovir complex is less
potent than cisplatin on a mole-equivalent basis. This behaviour might be related either to
pharmacokinetic reasons, being platinum-acyclovir a charged compound, or to a different
mechanism of action, as suggested by the absence of cross-resistance with cisplatin.
In order to address the mechanistic properties of the platinum-acyclovir complex with
respect to its anticancer activity, the sequence specificity of DNA modification and the
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DNA interstrand cross-linking ability were investigated and compared to those of cisplatin
and [Pt(dien)Cl]+, a well known antitumour-inactive platinum-triamine complex.
Figure 1. Primer extension footprinting assay of
platinum-treated pBR322 DNA. Circular pBR322
DNA (1.5x10" mol nucleotides) was reacted with
platinum complexes (drug/nucleotide 0.02) for 1
h at 37 C. The DNA was replicated in vitro with
Sequenase 2.0 enzyme and the products of
synthesis were analyzed on a sequencing gel in
parallel to a sequence ladder (lanes C, T, A and
G) performed on unreacted DNA. Lane 1,
[Pt(dien)Cl]+-modified DNA; lane 2, platinum-
acyclovir-modified DNA; lane 3, no reagent; lane
4, cisplatin-modified DNA.
In the primer extension footprinting assay
platinum adducts on DNA template can interfere
with the processivity of a polymerase, thus
determining premature chain terminations
corresponding to platinated sites. As shown in
Figure 1, all tested compounds are able to block
the Sequenase 2 enzyme and the main stop bands
appear at guanine residues. In agreement with
previous experiments performed with Klenow
polymerase (19) and Sequenase (14) the sites of
DNA synthesis termination on cisplatin-treated
DNA template (lane 4) correspond to runs oftwo
or more guanines. For d(pGG) sites polymerase
stops at the first platinated nucleotide, while for
the d(pG)5 site (bottom of the gel) the most
intense stop band, as evaluated by densitometric
analysis, corresponds to the second guanine (3’-5’
direction) ofthe template strand.
The platinum-acyclovir complex (lane 2) shows
minor affinity for multiple (>2) guanines, as
indicated by the low intensity of stop bands at the
d(pG)5 site.
The main bands appear at d(pGG) sites; however, differently from cisplatin, the DNA
polymerase stops at either of the two bases, and in some cases no band corresponds to
d(pGG) sites, suggesting that the reactivity of adjacent guanines with Pt-acyclovir is
influenced by neighbouring bases. Moreover platinum-acyclovir complex, unlike cisplatin,
determines additional s_[_op bands corresponding to cytosine residues in 3’GCT and 3’CGGC
sites. The [Pt(dien)Cl]- complex, lane 1, does not determine stop bands corresponding to
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isolated guanines and shows poor affinity for the d(pG)5 site; moreover, like platinum-
acyclovir, it determines stop bands at either of the two bases at selected d(pGG)
dinucleotide sites. The intensity of stop bands on [Pt(dien)Cl]+-treated DNA template is
lower than that on cisplatin-treated template. This result does not depend upon a lower
amount of platinum bound per nucleotide, indeed the experimental conditions employed
resulted in a higher level of platination with respect to cisplatin (19). One possible
explanation is that monofunctional adducts formed by [Pt(dien)Cl]+ are inherently less
effective than bifunctional adducts in inhibiting the DNA polymerase.
The nature of platinum-acyclovir adducts responsible for the polymerase block (i.e.
mono- or bifunctional type) is currently under investigation. The general pattern of the
footprinting experiment (more similar, in the number and intensity of stop lesions, to that of
[Pt(dien)Cl]+ than to that of cisplatin) and preliminary results obtained with terbium
fluorescent probe suggest that monofunctional adducts are predominant, even though some
bifunctional adducts cannot be excluded.
The kinetics of interstrand cross-link formation by platinum complexes reacting with
a natural DNA fragment is shown in Figure 2.
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Figure 2. Kinetics of the interstrand cross-linking in the Eco RI-linearized pGEM DNA by
platinum complexes (drug/nucleotide 0.001). The samples were analyzed on a denaturing
1% agarose gel and the percentage of cross-linked DNA was calculated from a
densitometric scan of resulting bands.
Both cisplatin and platinum-acyclovir complexes were effective as cross-linking
agents, while the [Pt(dien)C1]+ complex was completely inactive. In the case of Pt-
acyclovir, the rate of interstrand cross-link formation was slower than that of cisplatin, and
also the extent of reaction was lower. Assuming one ICL per DNA molecule, it can be
deduced that the ICLs formed by cisplatin after 24 h reaction time represented about 12%
of total platinum bound, whereas the ICLs formed by platinum-acyclovir represented only
3.7%. The interstrand cross-linking capability of platinum-acyclovir complex can be
explained, as reported by Leng et al. for the cis-[Pt(NH3)2(N7-N-methyl-2-
diazapyrenium)Cl]2+ complex (20), on the basis of a labilization ofthe aromatic base within
the double-stranded DNA resulting in the formation ofbifunctional adducts.
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CONCLUSION
In this work we report the synthesis of platinum(II)-acyclovir complexes and show
that [PtCl(NH3)2(acyclovir)]NO3, is endowed with both antiviral and anticancer activities.
On a mole-equivalent basis the platinum-acyclovir complex is less active than the parent
drugs, but it shows the same activity of cisplatin when administered at equitoxic dosages to
P388 leukaemia-bearing mice. Moreover the platinum-acyclovir complex is active against
the cisplatin-resistant P388 subline and is characterized by DNA interaction properties
different from those of cisplatin, thus suggesting that a different mechanism of action could
be operative.
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